Skip to main content
. 2024 Apr 24;10(2):e12465. [Article in Dutch] doi: 10.1002/trc2.12465

TABLE 4.

Minimal, mean, and maximal study durations (treatment plus recruitment) for Phase 1, Phase 2, and Phase 3 trials of DMT biologics, DMT small molecules, cognitive enhancing agents, and drugs for neuropsychiatric syndromes (prevention trials not included).

Therapeutic purpose Relative duration Phase 1 Phase 2 Phase 3 Total; weeks Total; years
DMT; biologic Minimal 49.0 47.9 104.3 201.2 3.9
Mean 141.9 218.9 302.3 663.1 12.7
Maximal 286.3 635.0 773.9 1695.2 32.5
DMT; small molecule Minimal 74.6 58.6 43.7 176.9 3.4
Mean 124.7 184.5 195.8 505.0 9.7
Maximal 191.3 495.9 291.7 978.9 18.8
Cognitive enhancing agent Minimal 53.9 52.1 156.6 262.6 5
Mean 136.8 178.9 206.7 522.4 10
Maximal 219.7 446.0 243.7 909.4 17.4
Drugs for NPS Minimal 191.9 52.3 79.0 323.2 6.2
Mean 194.3 165.6 219.5 579.4 11.1
Maximal 196.7 378.3 500.0 1075.0 20.6

Abbreviations: DMT, Disease‐modifying therapy; NPS, neuropsychiatric symptoms.